Charles J Rowe

US Patent:

7300668, Nov 27, 2007

Filed:

Oct 29, 2002

Appl. No.:

10/284039

Inventors:

Wendy E. Pryce Lewis - Watertown MA, US
Charles William Rowe - Medford MA, US
Michael J. Cima - Winchester MA, US
Peter A. Materna - Metuchen NJ, US

Assignee:

Massachusetts Institute of Technology - Cambridge MA

International Classification:

A61K 9/20
A61K 9/22
A61K 9/24

US Classification:

424472, 424464, 424468, 424471, 424473

Abstract:

The present invention includes controlled release dosage forms and methods of designing and manufacturing dosage forms to obtain specific release profiles, for example, zero-order release profiles, escalating release profiles or decreasing release profiles. The dosage forms of the present invention can include spatial variation of API concentration in the dosage form and can include nested regions. Dosage forms according to the present invention may be manufactured by any appropriate method for obtaining the internal structure as disclosed herein for producing zero-order release profiles and increasing or decreasing release profiles. The invention further includes methods of manufacturing such dosage forms, such as by three-dimensional printing, possibly also including compression of the dosage form after three-dimensional printing. The invention further includes methods of designing such dosage forms. Release profiles from non-uniform distributions of API concentration may be predicted based on simple experiments with uniform-concentration dosage forms.

US Patent:

7553855, Jun 30, 2009

Filed:

May 14, 2007

Appl. No.:

11/748073

Inventors:

Christopher R. Young - Waltham MA, US
Charles William Rowe - Medford MA, US

Assignee:

Vertex Pharmaceuticals Incorporated - Cambridge MA

International Classification:

A61K 31/47

US Classification:

514312

Abstract:

Pharmaceutical compositions including N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) and methods of using such compositions are described herein.

US Patent:

7820201, Oct 26, 2010

Filed:

Oct 22, 2007

Appl. No.:

11/876153

Inventors:

Wendy E. Pryce Lewis - Lexington MA, US
Charles W. Rowe - Medford MA, US
Michael J. Cima - Winchester MA, US
Peter A. Materna - Metuchen NJ, US

Assignee:

Massachusetts Institute of Technology - Cambridge MA

International Classification:

A61K 9/24
A61K 9/20
A61K 9/22
A61K 9/48

US Classification:

424472, 424451, 424453, 424468, 424473

Abstract:

The present invention includes controlled release dosage forms and methods of designing and manufacturing dosage forms to obtain specific release profiles, for example, zero-order release profiles, escalating release profiles or decreasing release profiles. The dosage forms of the present invention can include spatial variation of API concentration in the dosage form and can include nested regions. Dosage forms according to the present invention may be manufactured by any appropriate method for obtaining the internal structure as disclosed herein for producing zero-order release profiles and increasing or decreasing release profiles. The invention further includes methods of manufacturing such dosage forms, such as by three-dimensional printing, possibly also including compression of the dosage form after three-dimensional printing. The invention further includes methods of designing such dosage forms. Release profiles from non-uniform distributions of API concentration may be predicted based on simple experiments with uniform-concentration dosage forms.

US Patent:

7931914, Apr 26, 2011

Filed:

Oct 29, 2002

Appl. No.:

10/284430

Inventors:

Wendy E. Pryce Lewis - Watertown MA, US
Charles William Rowe - Medford MA, US
Michael J. Cima - Winchester MA, US
Peter A. Materna - Metuchen NJ, US

Assignee:

Massachusetts Institute of Technology - Cambridge MA

International Classification:

A61K 9/20
A61K 9/28
A61K 9/14
A61K 9/16
A61K 9/48
A61F 13/00

US Classification:

424464, 424451, 424452, 424463, 424465, 424474, 424489, 424490, 424422

Abstract:

A uniaxially compressed dosage form manufactured by three-dimensional printing that preserves the predetermined internal architecture of the dosage form while producing an improved surface finish. The compression compacts the dosage form, eliminating at least some of the void space that remains at the end of conventional three-dimensional printing. Surface finish obtained as a result of the uniaxial compression process can be essentially equal to that obtained from conventional tablet pressing. Additionally, the internal structure or spatial variation of composition of the dosage form is preserved during the pressing operation, with geometric shrinkage occurring mostly in the direction of the axis of pressing. Further, as a result of compression, a greater quantity of API can be packed into a given final volume of dosage form.

US Patent:

8076357, Dec 13, 2011

Filed:

May 26, 2009

Appl. No.:

12/471950

Inventors:

Christopher R. Young - Waltham MA, US
Charles William Rowe - Medford MA, US

Assignee:

Vertex Pharmaceuticals Incorporated - Cambridge MA

International Classification:

A61K 31/47

US Classification:

514312

Abstract:

Pharmaceutical compositions including N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) and methods of using such compositions are described herein.

US Patent:

20020106412, Aug 8, 2002

Filed:

Jul 10, 2001

Appl. No.:

09/904190

Inventors:

Charles Rowe - Medford MA, US
Michael Cima - Winchester MA, US
Wendy Pryce Lewis - Watertown MA, US

Assignee:

Therics, Inc - Princeton NJ

International Classification:

A61K009/16
A61K009/50

US Classification:

424/490000, 264/004000

Abstract:

A method and apparatus for controlling the migration of binder liquid in a bulk powder. The bulk powder may be deposited in a powder bed and contains at least two different substances, each in powder form. One substance gives the printed part its bulk properties, forms most of the powder, and preferably is either insoluble or not significantly soluble in the binder liquid. The other powder substance is a migration control substance. Upon interaction with the binder liquid, this substance may absorb the binder liquid and form a gel or dissolve into the binder liquid increasing viscosity thereby inhibiting binder migration. No chemical reactions occur between the binder liquid and any of the substances in the powder bed. In another embodiment of the instant invention, binder migration may be further controlled by first printing a barrier region in the powder bed containing the migration control substance. The instant invention provides functional and aesthetic advantages including more accurate release profiles in oral dosage forms and more dimensionally controlled edges and surfaces of parts. The result is sharper, more dimensionally controlled edges and surfaces of parts and sharper meetings of dissimilar binders in cases where more than one binder liquid is involved. The method is useful for printing pharmaceutical Oral Dosage Forms, attaining better control of the time release characteristics.

US Patent:

20030099708, May 29, 2003

Filed:

Nov 21, 2001

Appl. No.:

09/991556

Inventors:

Charles Rowe - Medford MA, US
Wendy Pryce Lewis - Watertown MA, US
Michael Cima - Winchester MA, US
Esteban Bornancini - North Wales PA, US
Jill Sherwood - Edison NJ, US
Christopher Gaylo - Princeton Junction NJ, US
James Fairweather - West Haven CT, US

Assignee:

Therics, Inc - Princeton NJ

International Classification:

A61K009/26
A61K009/16
A61K009/50

US Classification:

424/469000

Abstract:

The invention includes dispensing a suspension containing solid particles for use in manufacturing a dosage form or other biomedical article by 3DP. The suspension contains solid particles suspended in a liquid. The solid particles may be one or more Active Pharmaceutical Ingredients. The solid particles may be particles of material that are insoluble in the liquid, or they may be particles of a substance that have already dissolved in the liquid up to the saturation level and are present in a concentration beyond what can be dissolved. In addition to solid particles, the liquid may also contain other substances dissolved in it, either substances containing Active Pharmaceutical Ingredients (API) or substances without API. One aspect of the invention includes prevention of agglomeration by adding one or more of several categories of additives to the suspending liquid. Another aspect of the invention includes manipulating the surface charge of the particles in an API suspension to prevent particles from agglomerating. A further aspect of the invention includes an amorphous API that has a greater bioavailability than the corresponding crystalline material. Yet another aspect of the present invention includes a system for providing continuous circulation of the suspension such that the solid particles remain dispersed in the suspension.

US Patent:

20040062814, Apr 1, 2004

Filed:

Oct 14, 2003

Appl. No.:

10/685021

Inventors:

Charles Rowe - Medford MA, US
Michael Cima - Winchester MA, US
Wendy Pryce Lewis - Watertown MA, US
Donald Monkhouse - Radnor PA, US
Sandeep Kumar - Thousand Oaks CA, US
Jaedeok Yoo - East Windsor NJ, US

International Classification:

A61K009/14

US Classification:

424/489000

Abstract:

A method and apparatus for controlling the migration of binder liquid in a bulk powder. The bulk powder may be deposited in a powder bed and contains at least two different substances, each in powder form. One substance gives the printed part its bulk properties, forms most of the powder, and preferably is either insoluble or not significantly soluble in the binder liquid. The other powder substance is a migration control substance. Upon interaction with the binder liquid, this substance may absorb the binder liquid and form a gel or dissolve into the binder liquid increasing viscosity thereby inhibiting binder migration. No chemical reactions occur between the binder liquid and any of the substances in the powder bed. In another embodiment of the instant invention, binder migration may be further controlled by first printing a barrier region in the powder bed containing the migration control substance. The instant invention provides functional and aesthetic advantages including more accurate release profiles in oral dosage forms and more dimensionally controlled edges and surfaces of parts. The result is sharper, more dimensionally controlled edges and surfaces of parts and sharper meetings of dissimilar binders in cases where more than one binder liquid is involved. The method is useful for printing pharmaceutical Oral Dosage Forms, attaining better control of the time release characteristics.